KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis: The BE RADIANT Randomized Clinical Trial With Open-Label Extension.

Matthias Augustin, Steven R Feldman, Richard B Warren, April Armstrong, Ronald Vender, Anna López-Ferrer, William H Dawe, Jérémy Lambert, Balint Szilagyi, Bengt Hoepken, Rhys Warham, Alice B Gottlieb

JAMA Dermatol 162(4) 359-367

PMID41706476
PMCIDPMC12917748
DOI10.1001/jamadermatol.2025.6055
发表日期2026-02-18
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1.:研究设计图;Figure 2.:图注未提示 KM 曲线;Figure 3.:图注未提示 KM 曲线。
摘要

摘要

IMPORTANCE: Patient-reported outcome (PRO) assessments alongside clinical parameters help to holistically determine treatment benefits. OBJECTIVE: To assess PROs among bimekizumab-treated patients with moderate to severe plaque psoriasis. DESIGN, SETTING, AND PARTICIPANTS: The BE RADIANT multicenter, phase 3b randomized clinical trial and open-label extension (OLE) had a 48-week double-blinded period and 96-week OLE (3 years' total treatment). Patients initially received bimekizumab or secukinumab. At year 1 (week 48/OLE entry), bimekizumab-randomized patients continued bimekizumab treatment (continuous bimekizumab-treated patients) and secukinumab-randomized patients switched to bimekizumab (secukinumab/bimekizumab-treated patients). INTERVENTIONS: Continuous bimekizumab-treated patients received bimekizumab, 320 mg, every 4 weeks to week 16, then every 4 weeks or every 8 weeks to 1 year and into the OLE. Secukinumab/bimekizumab-treated patients received secukinumab, 300 mg, every 4 weeks to 1 year, then switched to bimekizumab, 320 mg, every 4 weeks or every 8 weeks. All received bimekizumab every 8 weeks by week 64. MAIN OUTCOMES AND MEASURES: Patient-reported itching/skin pain/scaling (Psoriasis Symptoms and Impacts Measure [P-SIM]) and concurrent achievement of Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) scores are reported (nonresponder imputation to 1 year; modified nonresponder imputation to 1-3 years). RESULTS: A total of 373 bimekizumab-treated and 370 secukinumab-treated patients were randomized at baseline; 336 and 318, respectively, entered the OLE. Among bimekizumab-randomized and secukinumab-randomized patients, 127 (34.0%) and 93 (25.1%) reported no itching; 278 (74.5%) and 222 (60.0%) no skin pain; and 172 (46.1%) and 80 (21.6%) no scaling at week 4, respectively; at year 1, rates remained higher in bimekizumab-randomized vs secukinumab-randomized patients (itching: 227 [60.9%] vs 178 [48.1%]; nominal P < .001; skin pain: 293 [78.6%] vs 262 [70.8%]; nominal P = .01; scaling: 263 [70.5%] vs 184 [49.7%]; nominal P < .001). Bimekizumab-randomized patients had greater concurrent achievement rates of PASI = 0 and DLQI 0/1 vs secukinumab-randomized patients (week 4: 43 [11.5%] vs 17 [4.6%]; nominal P < .001; year 1: 230 [61.7%] vs 158 [42.7%]; nominal P < .001). In patients entering the OLE, high P-SIM = 0 rates were maintained to year 3. At OLE entry, concurrent achievement of PASI = 0 and DLQI 0/1 was reported in 69.2% continuous bimekizumab-treated and 48.5% secukinumab/bimekizumab-treated patients. After switching, secukinumab/bimekizumab responses increased, and high rates were maintained to year 3 for both continuous bimekizumab and secukinumab/bimekizumab (62.2% and 63.8%, respectively). CONCLUSIONS AND RELEVANCE: In this randomized clinical trial and OLE, bimekizumab rapidly and durably improved symptoms/health-related quality of life to 3 years, demonstrating that clinical efficacy translates to quality of life improvements. Secukinumab-randomized patients reported improvements on switching to bimekizumab. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03536884.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1.BE RADIANT Study Design Diagram The BE RADIANT study design over 3 years has been published previously. 15 Secukinumab, 300 mg, was administered at baseline, weeks 1, 2, 3, and 4, then every 4 weeks for the remainder of the double-blinded treatment period. Following a protocol amendment, all patients receiving bimekizumab, 320 mg, every 4 weeks in the open-label extension period were switched to bimekizumab, 320 mg, every 8 weeks at the next scheduled clinic visit on or after the week 64 visit. PASI 90 indicates ≥90% improvement from baseline in Psoriasis Area and Severity Index.
非 KM Figure
Figure 2.Line Graphs of the Proportion of Patients Reporting No Symptoms (P-SIM = 0) Through 1 Year (Nonresponder Imputation) and 1 to 3 Years (Modified Nonresponder Imputation) Through 1 year, data are presented for all randomized patients in the double-blinded treatment period only. From 1 to 3 years, data are presented for patients who entered the open-label extension and received bimekizumab only. A total of 343 bimekizumab patients and 325 secukinumab patients completed week 48. P-SIM indicates Psoriasis Symptoms and Impacts Measure.
非 KM Figure
Figure 3.Stacked Bar Graphs of Dermatology Life Quality Index (DLQI) Total Score by Severity Categories Through 1 Year Data are presented for all randomized patients in the double-blinded treatment period only. Proportions of patients achieving DLQI 0/1 have been published previously for patients initially randomized to bimekizumab (n = 373) or secukinumab (n = 370) through the end of the double-blinded treatment period (week 48; using nonresponder imputation) 14 and through 3 years for patients who entered the open-label extension (using modified nonresponder imputation). 15
非 KM Figure